作为治疗2型糖尿病的GIPR/GLP-1R/GCGR三原体的新
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
ACS medicinal chemistry letters
|August 20, 2025
概括
这项专利申请引入了针对GIPR,GLP-1R和GCGR的新型三种药物. 这些化合物对治疗2型糖尿病,肥胖和脂肪肝有很大的希望.
科学领域:
- 医学化学
- 药理学
- 内分泌学
背景情况:
- 肥胖和2型糖尿病 (T2DM) 是全球重要的健康挑战.
- 目前对T2DM和肥胖的治疗有局限性,需要新的治疗策略.
- 针对胃抑制性多受体 (GIPR) 和葡萄糖类-1受体 (GLP-1R) 的受体激活剂已显示出治疗效果.
研究的目的:
- 在GIPR,GLP-1R和GCGR上表现出一种新型的三原剂.
- 为治疗代谢疾病提供具有独特药理特征的化合物.
- 为开发T2DM,肥胖和非酒精性脂肪肝疾病的新疗法提供基础.
主要方法:
- 三原剂的合成和表征.
- 在体外和体内对受体活性进行药理评估.
- 研究结构与活性关系以优化化合物特性.
主要成果:
- 在GIPR,GLP-1R和GCGR表现出强有力的和选择性的双重或三重激应剂的鉴定.
- 在临床前模型中证明了有利的药理动力学特性和体内疗效.
- 建立一种新的化学支架,用于代谢药物发现.
结论:
- 这种新型的三种药物代表了一种有前途的新疗法.
- 这些化合物可用于治疗2型糖尿病,肥胖和非酒精性脂肪肝.
- 进一步开发这些三种药物可能会改善患者代谢障碍的结果.
相关概念视频
Glucagon-like Receptor Agonists
415
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
415
Dipeptidyl Peptidase 4 Inhibitors
249
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
249
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K


